Prothena Corporation PLC
PRTA
ISIN IE00B91XRN20 / Valor 20224443
Prothena Corporation PLC
UMushroom community rating:
About company
Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Net Loss
For the fourth quarter and full year of 2023, Prothena Corporation PLC reported a net loss of $67.5 million and $147.0 million, respectively. This compares to a net income of $6.3 million and a net loss of $116.9 million for the fourth quarter and full year of 2022, respectively.
Revenue
Prothena Corporation PLC reported total revenue of $0.3 million for the fourth quarter of 2023 and $91.4 million for the full year of 2023. This is a significant change from the $49.9 million and $53.9 million reported for the fourth quarter and full year of 2022, respectively.
Research and Development Expenses
Research and development (R&D) expenses for Prothena Corporation PLC totaled $61.9 million for the fourth quarter of 2023 and $220.6 million for the full year. This is an increase from $36.9 million and $135.6 million for the same periods in 2022, respectively.
General and Administrative Expenses
General and administrative (G&A) expenses for Prothena Corporation PLC were $16.9 million for the fourth quarter of 2023 and $61.8 million for the full year. This compares to $13.1 million and $49.9 million for the fourth quarter and full year of 2022, respectively.
Cash Position
As of December 31, 2023, Prothena Corporation PLC had $621.0 million in cash, cash equivalents, and restricted cash, with no debt. As of February 9, 2024, the company had approximately 53.7 million ordinary shares outstanding.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1744 M
Market cap (USD)
121,402
Daily traded volume (Shares)
22.7 / 21.77
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
